Total Payments
$1.9M
2023 Payments
$69,250
Companies
3
Transactions
283
Payment Breakdown by Category
Research$1.4M (73.0%)
Consulting$526,595 (27.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 82 | 73.0% |
| Consulting Fee | $526,595 | 201 | 27.0% |
Payments by Type
Research
$1.4M
82 transactions
General
$526,595
201 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1.3M | 75 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $526,595 | 201 | $0 (2021) |
| Eli Lilly and Company | $104,823 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $69,250 | 12 | E.R. Squibb & Sons, L.L.C. ($63,710) |
| 2022 | $269,367 | 17 | E.R. Squibb & Sons, L.L.C. ($250,699) |
| 2021 | $565,080 | 78 | Merck Sharp & Dohme Corporation ($300,360) |
| 2020 | $545,720 | 82 | E.R. Squibb & Sons, L.L.C. ($353,955) |
| 2019 | $426,520 | 85 | E.R. Squibb & Sons, L.L.C. ($393,538) |
| 2018 | $6,985 | 7 | Eli Lilly and Company ($5,498) |
| 2017 | $65,730 | 2 | Eli Lilly and Company ($65,730) |
All Payment Transactions
283 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $87.50 | Research |
| Study: Phase I/II FIH STING Monotherapy/Combination in advanced solid tumors | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $40,920.00 | Research |
| Study: Phase III Randomized Study of Opdivo+Doc vs Doc in chemo-nave mCRPC (FA-OS) • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $9,795.00 | Research |
| Study: Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par • Category: Oncology | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,540.00 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $3,240.00 | Research |
| Study: Phase III Neoadjuvant NSCLC nivo+chemo - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $2,380.00 | Research |
| Study: Phase III 1L NSCLC nivo+ipi+chemo vs chemo in PDL-1 all comers • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $2,160.00 | Research |
| Study: Phase III 1L Esophageal (Nivo+Ipi vs Nivo+CT vs CT) • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $2,160.00 | Research |
| Study: Phase III NSCLC 1L (combo) - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Na ve Stage IV or Recurrent • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: Phase II Nivo orc Nivo combo in mCRC MSI-H & non MSI-H - A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $780.00 | Research |
| Study: Phase III 1L Gastric (nivo+ipi vs nivo+CT vs CT) • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $700.00 | Research |
| Study: Phase III 1L Metastatic RCC Nivo/Ipi/Cabo • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $87.50 | Research |
| Study: Progressive Combinations- Metastatic ER+/HER2- Breast Cancer | ||||||
| 07/06/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $175.00 | Research |
| Study: Phase IIB Signal Detection Single arm, PD-1 (TNBC, SCLC, pancreatic, gastric, bladder, Ovarian) Mono and Combo • Category: Oncology | ||||||
| 04/06/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $8,767.50 | Research |
| Study: Phase IIB Colon Cancer MSI nivo mono and combo • Category: Oncology | ||||||
| 02/03/2022 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $1,838.00 | Research |
| Study: Fuc-GM1 nivo chemo vs nivo chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | ||||||
| 02/03/2022 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $87.50 | Research |
| Study: Phase I II FIH STING Monotherapy Combination in advanced solid tumors | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $105,370.00 | Research |
| Study: Phase III Randomized Study of Opdivo Doc vs Doc in chemo CRPC • Category: Oncology | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $45,238.00 | Research |
| Study: Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec • Category: Oncology | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $24,475.00 | Research |
| Study: Ph III 1L Metastatic Melanoma nivo NKTR 214 vs nivo mono | ||||||
| 01/05/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $18,668.00 | Research |
| Study: LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $13,788.00 | Research |
| Study: Phase III Neoadjuvant NSCLC nivo chemo - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC • Category: Oncology | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $13,075.00 | Research |
| Study: Phase III 1L Metastatic RCC Nivo Ipi Cabo • Category: Oncology | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $10,015.00 | Research |
| Study: Phase III 1L Esophageal Nivo Ipi vs Nivo CT vs CT • Category: Oncology | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $9,835.00 | Research |
| Study: Phase III 1L NSCLC nivo ipi chemo vs chemo in PDL-1 all comers • Category: Oncology | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $6,975.00 | Research |
| Study: Phase III NSCLC 1L combo - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Na ve Stage IV or Recurrent N • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III 1L Esophageal Nivo Ipi vs Nivo CT vs CT | E.R. Squibb & Sons, L.L.C. | $158,575 | 4 |
| Phase III 1L Gastric nivo ipi vs nivo CT vs CT | E.R. Squibb & Sons, L.L.C. | $146,203 | 4 |
| Phase III 1L NSCLC nivo ipi chemo vs chemo in PDL-1 all comers | E.R. Squibb & Sons, L.L.C. | $123,210 | 4 |
| Phase III Randomized Study of Opdivo Doc vs Doc in chemo CRPC | E.R. Squibb & Sons, L.L.C. | $105,370 | 1 |
| Phase IIB Colon Cancer MSI nivo mono and combo | E.R. Squibb & Sons, L.L.C. | $95,908 | 4 |
| Phase III Neoadjuvant NSCLC nivo chemo | E.R. Squibb & Sons, L.L.C. | $91,240 | 3 |
| Phase III NSCLC 1L combo | E.R. Squibb & Sons, L.L.C. | $87,055 | 3 |
| Phase III 1L Metastatic RCC Nivo Ipi Cabo | E.R. Squibb & Sons, L.L.C. | $74,963 | 4 |
| Ph III 1L Metastatic Melanoma nivo NKTR 214 vs nivo mono | E.R. Squibb & Sons, L.L.C. | $69,498 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY | Eli Lilly and Company | $69,290 | 2 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC | E.R. Squibb & Sons, L.L.C. | $55,568 | 3 |
| Phase IIB Signal Detection Single arm, PD-1 TNBC, SCLC, pancreatic, gastric, bladder, Ovarian Mono and Combo | E.R. Squibb & Sons, L.L.C. | $47,163 | 3 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec | E.R. Squibb & Sons, L.L.C. | $45,238 | 1 |
| Phase III Randomized Study of Opdivo+Doc vs Doc in chemo-nave mCRPC (FA-OS) | E.R. Squibb & Sons, L.L.C. | $40,920 | 1 |
| Phase III Randomized Study of Opdivo+Doc vs Doc in chemo-nave mCRPC | E.R. Squibb & Sons, L.L.C. | $37,090 | 1 |
| Phase I IIA FIH Nivo Combination with Monotherapy Run-in | E.R. Squibb & Sons, L.L.C. | $31,180 | 3 |
| LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $28,056 | 2 |
| Multi-Center Phase II Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combinatiion with Ipilimumab followed by Nivolumab Monotherapy | E.R. Squibb & Sons, L.L.C. | $17,365 | 3 |
| Phase IIB 1L NSCLC nivo ipi and nivo ipi chemo | E.R. Squibb & Sons, L.L.C. | $15,753 | 3 |
| Phase III Neoadjuvant NSCLC nivo chemo - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC | E.R. Squibb & Sons, L.L.C. | $13,788 | 1 |
| Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par | E.R. Squibb & Sons, L.L.C. | $9,795 | 1 |
| Phase I II FIH Monotherapy Combination | E.R. Squibb & Sons, L.L.C. | $8,138 | 2 |
| Phase III NSCLC 1L combo - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Na ve Stage IV or Recurrent N | E.R. Squibb & Sons, L.L.C. | $6,975 | 1 |
| Phase IIB 1L NSCLC nivo ipi and nivo ipi chemo - A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy (part 2) as First Line Therapy in Stage IV Non- Small Cell Lung Cancer (NSCLC) | E.R. Squibb & Sons, L.L.C. | $5,640 | 1 |
| A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | Eli Lilly and Company | $5,540 | 1 |
| Phase III FIH MonotherapyCombination | E.R. Squibb & Sons, L.L.C. | $5,338 | 1 |
| Phase III Peri-Adjuvant NSCLC Nivo Mono | E.R. Squibb & Sons, L.L.C. | $3,850 | 2 |
| Phase III Neoadjuvant NSCLC nivo+chemo - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC | E.R. Squibb & Sons, L.L.C. | $3,240 | 1 |
| Ph III 1L Metastatic Melanoma nivoNKTR 214 vs nivo mono | E.R. Squibb & Sons, L.L.C. | $3,170 | 1 |
| Phase III 1L NSCLC nivo+ipi+chemo vs chemo in PDL-1 all comers | E.R. Squibb & Sons, L.L.C. | $2,380 | 1 |
| Phase III 1L Esophageal (Nivo+Ipi vs Nivo+CT vs CT) | E.R. Squibb & Sons, L.L.C. | $2,160 | 1 |
| Phase III NSCLC 1L (combo) - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Na ve Stage IV or Recurrent | E.R. Squibb & Sons, L.L.C. | $2,160 | 1 |
| A PHASE II SINGLE ARM PILOT STUDY OF THE CHK1-2 INHIBITOR -LY2606368- IN WOMEN WITH BRCA1-2 MUTATION ASSOCIATED BREAST OR OVARIAN CANCER, NON-HIGH RISK TRIPLE NEGATIVE BREAST CANCER, AND HIGH GRADE SEROUS OVARIAN CANCER AT LOW GENETIC RISK | Eli Lilly and Company | $1,938 | 2 |
| Fuc-GM1 nivo chemo vs nivo chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | E.R. Squibb & Sons, L.L.C. | $1,838 | 1 |
| Phase II Nivo orc Nivo combo in mCRC MSI-H & non MSI-H - A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer | E.R. Squibb & Sons, L.L.C. | $1,400 | 1 |
| Ph IIIII 2-3L I-O Refract NKTRNivodoce. vs Nivodoce. vs PBOdoce. | E.R. Squibb & Sons, L.L.C. | $1,313 | 1 |
| A Study of Multiple Immune and Chemotherapeutic Treatment Combinations in Participants with Metastatic ER HER2- Breast Cancer | E.R. Squibb & Sons, L.L.C. | $1,138 | 1 |
| Phase III 1L Gastric (nivo+ipi vs nivo+CT vs CT) | E.R. Squibb & Sons, L.L.C. | $780.00 | 1 |
| Phase III 1L Metastatic RCC Nivo/Ipi/Cabo | E.R. Squibb & Sons, L.L.C. | $700.00 | 1 |
| Progressive Combinations- Metastatic ER HER2- Breast Cancer | E.R. Squibb & Sons, L.L.C. | $262.50 | 1 |
| Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | E.R. Squibb & Sons, L.L.C. | $262.00 | 1 |
| Phase IIB Signal Detection Single arm, PD-1 (TNBC, SCLC, pancreatic, gastric, bladder, Ovarian) Mono and Combo | E.R. Squibb & Sons, L.L.C. | $175.00 | 1 |
| Subcutaneous Ipilumamab Monotherapy and in Combination with Subcutaneous Nivolumab in Patients with Solid Tumors | E.R. Squibb & Sons, L.L.C. | $175.00 | 1 |
| Phase I II FIH STING Monotherapy Combination in advanced solid tumors | E.R. Squibb & Sons, L.L.C. | $87.50 | 1 |
| Phase I/II FIH STING Monotherapy/Combination in advanced solid tumors | E.R. Squibb & Sons, L.L.C. | $87.50 | 1 |
| Progressive Combinations- Metastatic ER+/HER2- Breast Cancer | E.R. Squibb & Sons, L.L.C. | $87.50 | 1 |
About Dr. Eric Perlman, M.D
Dr. Eric Perlman, M.D is a Diagnostic Radiology healthcare provider based in Kendall Park, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326058090.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Perlman, M.D has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $69,250 received in 2023. These payments were reported across 283 transactions from 3 companies. The most common payment nature is "" ($1.4M).
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Kendall Park, NJ
- Active Since 08/08/2006
- Last Updated 07/08/2007
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1326058090
Products in Payments
- OPDIVO (Biological) $1.2M
- KEYTRUDA (Biological) $374,700
- MK-7339 (Drug) $90,718
- CYRAMZA (Drug) $69,290
- LENVIMA (Drug) $4,113
- V938 (Biological) $2,275
- MK-4280 (Biological) $700.00
- LYNPARZA (Biological) $175.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Kendall Park
Dr. Gregory Kaufmann, M.d, M.D
Diagnostic Radiology — Payments: $699,440
Diagnostic Radiology $699,440
Dr. John Ghazi, M.d, M.D
Diagnostic Radiology — Payments: $443,331
Diagnostic Radiology $443,331
Dr. Gerard Compito, M.d, M.D
Diagnostic Radiology — Payments: $422,308
Diagnostic Radiology $422,308
Dr. Robert Ford, M.d, M.D
Diagnostic Radiology — Payments: $240,605
Diagnostic Radiology $240,605
Dr. Samuel Greene, M.d, M.D
Diagnostic Radiology — Payments: $131,187
Diagnostic Radiology $131,187
Dr. Jonathan Lebowitz, M.d, M.D
Diagnostic Radiology — Payments: $9,174
Diagnostic Radiology $9,174